CBIO
Crescent Biopharma, Inc.
13.90$
-2.8%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 363.2% | -68.6% | -389.2% | -28.5% | -41.1% | -160,709.5% | – | – | – | -386.1% | -4,957.0% | -61,943.3% | -348,799.0% | – | -659.6% | |
| 2.2% | 0.7% | 3.3% | 1.1% | 1.0% | 1,029.9% | – | – | – | 2.7% | 22.8% | 276.2% | 1,533.0% | – | 0.8% | |
| 9.9% | 2.7% | 10.7% | 10.9% | 11.6% | 16,025.8% | – | – | – | 67.9% | 524.9% | 5,143.4% | 35,604.8% | – | 122.6% | |
| 511.5% | -96.0% | -137.6% | 33.6% | 10.0% | -5,820.2% | – | – | – | 38.7% | -100.5% | -6,215.9% | -25,591.3% | – | -123.3% | |
| 4.8% | 2.1% | 2.1% | 1.4% | 1.3% | 3,806.5% | – | – | – | 0.7% | 1.3% | 112.3% | 213.9% | – | 672.4% | |
| -6.3% | -2.1% | -2.1% | -1.4% | -1.3% | -3,806.5% | – | – | – | -0.7% | -1.3% | -112.3% | -213.9% | – | -672.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | |
| -0.6% | 0.0% | 14.0% | 381.9% | 0.6% | 127,970.5% | – | – | – | 178.5% | 924.7% | 5,543.2% | 288,235.1% | – | 2,978.5% | |
| 356.3% | -70.8% | -377.2% | 352.0% | -41.8% | -36,545.5% | – | – | – | -208.3% | -4,033.6% | -56,512.4% | -60,777.9% | – | 1,646.4% | |
| 358.4% | -70.7% | -391.2% | -29.9% | -42.4% | -164,516.0% | – | – | – | -386.8% | -4,958.3% | -62,055.6% | -349,013.0% | – | -1,332.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.